HomeCompareTRSBF vs JEPI

TRSBF vs JEPI: Dividend Comparison 2026

TRSBF yields 1.22% · JEPI yields 8.56%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TRSBF wins by $9.05M in total portfolio value· pulled ahead in Year 4
10 years
TRSBF
TRSBF
● Live price
1.22%
Share price
$2.61
Annual div
$0.03
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$9.08M
Annual income
$7,845,769.56
Full TRSBF calculator →
JEPI
JPMorgan Equity Premium Income ETF
● Live price
8.56%
Share price
$55.65
Annual div
$4.76
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.3K
Annual income
$1,573.67
Full JEPI calculator →

Portfolio growth — TRSBF vs JEPI

📍 TRSBF pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTRSBFJEPI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TRSBF + JEPI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TRSBF pays
JEPI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TRSBF
Annual income on $10K today (after 15% tax)
$103.69/yr
After 10yr DRIP, annual income (after tax)
$6,668,904.13/yr
JEPI
Annual income on $10K today (after 15% tax)
$727.38/yr
After 10yr DRIP, annual income (after tax)
$1,337.62/yr
At 15% tax rate, TRSBF beats the other by $6,667,566.51/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TRSBF + JEPI for your $10,000?

TRSBF: 50%JEPI: 50%
100% JEPI50/50100% TRSBF
Portfolio after 10yr
$4.56M
Annual income
$3,923,671.61/yr
Blended yield
86.13%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TRSBF buys
0
JEPI buys
0
No recent congressional trades found for TRSBF or JEPI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTRSBFJEPI
Forward yield1.22%8.56%
Annual dividend / share$0.03$4.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%0%
Portfolio after 10y$9.08M$29.3K
Annual income after 10y$7,845,769.56$1,573.67
Total dividends collected$8.96M$12.0K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: TRSBF vs JEPI ($10,000, DRIP)

YearTRSBF PortfolioTRSBF Income/yrJEPI PortfolioJEPI Income/yrGap
1$10,944$243.97$11,276$855.74$332.00JEPI
2$12,209$499.06$12,675$926.02$466.00JEPI
3$14,104$1,040.65$14,207$999.01$103.00JEPI
4← crossover$17,339$2,247.09$15,878$1,074.57+$1.5KTRSBF
5$23,716$5,163.36$17,697$1,152.57+$6.0KTRSBF
6$38,577$13,200.74$19,674$1,232.87+$18.9KTRSBF
7$81,413$40,135.71$21,815$1,315.29+$59.6KTRSBF
8$245,435$158,323.22$24,131$1,399.68+$221.3KTRSBF
9$1,154,758$892,143.08$26,630$1,485.86+$1.13MTRSBF
10$9,081,361$7,845,769.56$29,323$1,573.67+$9.05MTRSBF

TRSBF vs JEPI: Complete Analysis 2026

TRSBFStock

3SBio Inc., an investment holding company, researches, develops, manufactures, markets, and sells biopharmaceutical products in the People's Republic of China. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; EPIAO and SEPO recombinant human erythropoietins to treat anemia; and Cipterbin for HER2-positive metastatic breast cancer in combination with chemotherapy. It also offers Mandi to treat male alopecia and alopecia areata; Xenopax for preventing acute rejection after renal transplant; Byetta for the glycemic control in patients with type 2 diabetes; Qiming Keli to treat retinopathy caused by type 2 diabetic; Aiyishu for iron-deficiency anemia; and SPARIN, an injectable low-molecular-weight heparin calcium for the treatment of prophylaxis and deep vein thrombosis, as well as for the prevention of clotting during hemodialysis. In addition, it offers Intefen, a recombinant human interferon to treat lymphatic or hematopoietic malignancies and viral infections; and Inleusin, a human interleukin2 for the treatment of renal cell carcinoma, melanoma, and thoracic fluid build-up. Further, the company provides trading, project management and consultation, technology, and agricultural services. It has collaboration agreements with companies, such as AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and Dana–Farber Cancer Institute. The company was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.

Full TRSBF Calculator →

JEPIETF

The fund seeks to provide the majority of the returns associated with its primary benchmark, the Standard & Poor's 500 Total Return Index (S&P 500 Index), while exposing investors to less risk through lower volatility and still offering incremental income. Under normal circumstances, the fund invests at least 80% of its assets in equity securities. It may also invest in other equity securities not included in the S&P 500 Index.

Full JEPI Calculator →
📬

Get this TRSBF vs JEPI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TRSBF vs SCHDTRSBF vs OTRSBF vs KOTRSBF vs MAINTRSBF vs JEPQTRSBF vs XYLDTRSBF vs DIVOTRSBF vs QYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.